Drug
Rotigotine
Rotigotine: highest development phase Phase 3, developed by UCB. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rotigotine NCT00263068 | Phase 3 | Restless Legs Syndrome |
| Rotigotine NCT00593606 | Phase 3 | Parkinson's Disease |
| Rotigotine NCT01646268 | Phase 3 | IDIOPATHIC PARKINSON'S DISEASE |
| Rotigotine NCT01536015 | Phase 3 | Advanced Parkinson's Disease |
Latest
No recent events.
Follow Rotigotine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.